acetylcholinesterase inhibitorsdonanemabAducanumablecanemabAlzheimer’s diseaseFDAADMCImild cognitive impairmentU.S. Food and Drug Administration+2 more
… questioned relative to existing symptomatic treatments such as acetylcholinesterase inhibitors (AChEI),2 which as older oral (or transdermal) agents are cheap…